Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Zepatier Resubmission Journey: From FDA CRL to Approval

Categories: Advanced Tissue Products / Accelerated Approval Pathways / Cell Therapy
The Zepatier Resubmission Journey: From FDA CRL to Approval

Hello Regulatory Scientists,

Today, let’s explore the journey of Zepatier (elbasvir/grazoprevir) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today.

Regulatory History and Initial Submission

Drug: Zepatier (elbasvir/grazoprevir) Mechanism of Action: NS5A inhibitor (elbasvir) and NS3/4A protease inhibitor (grazoprevir), which work together to inhibit the replication of the hepatitis C virus (HCV) Indication: Treatment of chronic hepatitis C virus (HCV) infection Initial Submission Date: May 2015

The Complete Response Letter (CRL)

CRL Date: October 2015 CRL Concerns:

1. Safety Data: The FDA requested more information on liver enzyme elevations observed in some patients during clinical trials.

2. Drug-Drug Interactions: Concerns about potential interactions with other commonly used medications, which required further investigation.

3. Manufacturing Issues: Issues related to the consistency and quality of the drug’s manufacturing process.

Resubmission Strategy

Merck, the company behind Zepatier, implemented a comprehensive strategy to address the FDA’s concerns:

1. Enhanced Safety Monitoring: Provided additional data and analyses on the liver enzyme elevations, with a focus on understanding and mitigating the risks.

2. Drug-Drug Interaction Studies: Conducted further studies to evaluate potential interactions with other medications, ensuring comprehensive data on safety and efficacy.

3. Improved Manufacturing Processes: Implemented improvements in the manufacturing process to ensure consistency and quality.

4. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions.

Resubmission Date: November 2015

Outcome

Approval Date: January 2016 Zepatier was approved for the treatment of chronic hepatitis C virus (HCV) infection, offering a new option for patients and marking a significant milestone in the management of HCV.

Lessons Learned

The journey of Zepatier from CRL to approval highlights several key lessons for drug developers:

1. Robust Safety Data: Ensuring comprehensive safety data, particularly for any observed adverse effects, is crucial to addressing FDA concerns.

2. Thorough Drug-Drug Interaction Studies: Evaluating potential interactions with other medications can help ensure a drug’s safety profile.

3. Improved Manufacturing Standards: Ensuring the quality and consistency of the manufacturing process can prevent regulatory setbacks.

4. Effective Use of Advisory Committees: Leveraging advisory committees can provide valuable feedback and support the resubmission process.

5. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations.

Relevance for Current Drug Developers

For companies developing drugs today, the Zepatier case underscores the importance of strategic planning and meticulous attention to detail in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval:

1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including safety data and manufacturing processes, meet FDA standards.

2. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review.

3. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process.

4. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns.

5. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission.

By learning from the Zepatier resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval.

Stay diligent and strategic,

CERES Regulatory Services

—

Picture of Asad Khan
Asad Khan